FlowTriever All-Comer Registry for Patient Safety and Hemodynamics
Completed · NCT03761173
Conditions: PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
At a glance
- Research payments reported, 2025
- $4,260
- U.S. investigators named
- 2
- Sites paid
- 0
- Planned or actual enrollment
- 1,200
About the trial
- Sponsor
- Inari Medical
- Tested
- FlowTriever System (device), Anticoagulation Agents (drug)
- Dates
- Started 2018-12-15; completion 2024-09-04
- Results posted
- Yes
To evaluate the safety and effectiveness of the FlowTriever System for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism (PE). The use of the device will be assessed in a real-world population, with eligibility criteria that closely approximate its use in clinical practice. Up to 300 additional patients with anticoagulation treatment as the initial planned primary treatment strategy for intermediate risk PE will also be evaluated (US only).
From ClinicalTrials.gov, last updated 2025-10-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Stryker Corporation reported $4,260 in research payments for this study in 2025 (2 payments).
Products named: Flowtriever Catheter, S
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Gregory J. Woodhead, M.D., PH.D. Interventional Radiology · Tucson, AZ
- Mitchell Weinberg, MD Interventional Cardiology · Manhasset, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $4,260
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.